RecruitingPhase 2NCT07203001

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

Studying Adult-onset Still disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Novartis Pharmaceuticals
Intervention
MAS825(drug)
Enrollment
20 enrolled
Eligibility
1-100 years · All sexes
Timeline
20252029

Study locations (20)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07203001 on ClinicalTrials.gov

Other trials for Adult-onset Still disease

Additional recruiting or active studies for the same condition.

See all trials for Adult-onset Still disease

← Back to all trials